Moreover, the unique binding mode of TG6-129 opens up new possibilities for the development of dual antagonists, which could offer enhanced therapeutic efficacy in conditions where both EP2 and EP4 signaling contribute to pathology, such as cancer and inflammatory diseases. This evidence concerns the gene TGM6 and cancer.